SK18722001A3 - Inhibítory integrínu ALFAvBETA6 - Google Patents

Inhibítory integrínu ALFAvBETA6 Download PDF

Info

Publication number
SK18722001A3
SK18722001A3 SK1872-2001A SK18722001A SK18722001A3 SK 18722001 A3 SK18722001 A3 SK 18722001A3 SK 18722001 A SK18722001 A SK 18722001A SK 18722001 A3 SK18722001 A3 SK 18722001A3
Authority
SK
Slovakia
Prior art keywords
asp
leu
arg
ser
thr
Prior art date
Application number
SK1872-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Alfred Jonczyk
Beate Diefenbach
Ulrich Groth
Gunther Zischinsky
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK18722001A3 publication Critical patent/SK18722001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SK1872-2001A 1999-06-26 2000-06-13 Inhibítory integrínu ALFAvBETA6 SK18722001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19929410A DE19929410A1 (de) 1999-06-26 1999-06-26 Inhibitoren des Integrins avß6
PCT/EP2000/005404 WO2001000660A1 (de) 1999-06-26 2000-06-13 INHIBITOREN DES INTEGRINS αv$(g)b¿6?

Publications (1)

Publication Number Publication Date
SK18722001A3 true SK18722001A3 (sk) 2002-05-09

Family

ID=7912712

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1872-2001A SK18722001A3 (sk) 1999-06-26 2000-06-13 Inhibítory integrínu ALFAvBETA6

Country Status (17)

Country Link
EP (1) EP1189930A1 (ko)
JP (1) JP2003503422A (ko)
KR (1) KR20020015704A (ko)
CN (1) CN1358195A (ko)
AR (1) AR024472A1 (ko)
AU (1) AU771099B2 (ko)
BR (1) BR0011954A (ko)
CA (1) CA2377224A1 (ko)
CZ (1) CZ20014484A3 (ko)
DE (1) DE19929410A1 (ko)
HU (1) HUP0201729A3 (ko)
MX (1) MXPA01013247A (ko)
NO (1) NO20016341L (ko)
PL (1) PL352374A1 (ko)
SK (1) SK18722001A3 (ko)
WO (1) WO2001000660A1 (ko)
ZA (1) ZA200200673B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
ATE394415T1 (de) * 2003-02-06 2008-05-15 Merck Patent Gmbh Peptidische sulfonamide
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
BRPI0715141A2 (pt) 2006-08-03 2013-06-04 Astrazeneca Ab agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado
IL266343B2 (en) * 2016-11-01 2024-01-01 Arrowhead Pharmaceuticals Inc Ligands of alpha-V beta-6 integrin and their uses
BR112020006901A2 (pt) 2017-11-01 2020-10-13 Arrowhead Pharmaceuticals, Inc. ligantes de integrina e usos dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511477A (ja) * 1991-05-14 1994-12-22 ボード　オブ　リージェンツ　オブ　ザ　ユニバーシティ　オブ　オクラホマ 炎症のペプチド阻害剤
ATE286742T1 (de) * 1997-08-08 2005-01-15 Univ California Behandlung von nierenfibrose durch antikörper gegen integrin alpha-v-beta 6
CN1335853A (zh) * 1998-12-19 2002-02-13 默克专利股份公司 整联蛋白αvβb的抑制剂

Also Published As

Publication number Publication date
DE19929410A1 (de) 2000-12-28
BR0011954A (pt) 2002-05-07
EP1189930A1 (de) 2002-03-27
HUP0201729A2 (en) 2002-08-28
WO2001000660A1 (de) 2001-01-04
CN1358195A (zh) 2002-07-10
NO20016341D0 (no) 2001-12-21
AU771099B2 (en) 2004-03-11
NO20016341L (no) 2002-02-25
ZA200200673B (en) 2003-04-24
AU6263000A (en) 2001-01-31
HUP0201729A3 (en) 2005-01-28
AR024472A1 (es) 2002-10-02
JP2003503422A (ja) 2003-01-28
MXPA01013247A (es) 2002-07-02
CZ20014484A3 (cs) 2002-04-17
CA2377224A1 (en) 2001-01-04
KR20020015704A (ko) 2002-02-28
PL352374A1 (en) 2003-08-25

Similar Documents

Publication Publication Date Title
US6001961A (en) Cyclic adhesion inhibitors
AU772782B2 (en) Cyclic peptide derivatives as inhibitors of integrin alphavbeta6
CZ20012212A3 (cs) Peptidická sloučenina, její použití a farmaceutický prostředek, který ji obsahuje
SK18722001A3 (sk) Inhibítory integrínu ALFAvBETA6
SK115696A3 (en) Biotinylated peptide derivative, preparation method and use thereof and pharmaceutical composition containing them
AU770295B2 (en) AlphaVbetaB integrin inhibitors
US7759302B2 (en) Peptidic sulfonamides
MXPA01006229A (en) &agr;v